Post-coronavirus Disease-2019 Fatigue
Risk Factors for Post-coronavirus Disease-2019 Fatigue: a Prospective Case-control Study
1 other identifier
observational
144
1 country
1
Brief Summary
Background: COVID-19 is consistently spreading throughout the world, and the number of recovered patients is steadily increasing. Accordingly, a significant number of individuals will develop persisting post-COVID symptoms, while many of them will report on lasting fatigue. The main objective of the current study is to assess risk factors for the development of post-COVID-19 fatigue symptoms. As a secondary aim, the current study is intended to identify pathophysiology and explanatory mechanisms for the post-COVID-19 fatigue. Study design and population: a nested case-control study will be conducted at Rabin Medical Center (RMC), Beilinson Hospital. RMC runs a post-COVID-19 clinic for adult (age ≥18 years) recovered individuals (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), who are invited for a comprehensive medical evaluation. During a visit, all individuals undergo pulmonary function testing and an evaluation by an infectious diseases physician, a pulmonologist, and a social worker. The cohort of recovered COVID-19 individuals evaluated at RMC will serve as the population from which the current study participants will be consecutively sampled. The cases would be defined as such if report on lasting fatigue symptoms which appeared following COVID-19, while at least two months have elapsed since COVID-19 diagnosis and the lasting fatigue symptoms are present for at least six weeks. The controls would be defined as those that did not report on fatigue symptoms at any time point since one month following their diagnosis with COVID-19. Evaluation protocol of cases and controls: All participating individuals (cases and controls) will be assessed following the study protocol. The assessment will be conducted as follows: First assessment meeting (approximately one hour long) in which the participant will undergo physical examination and blood tests, fill the study questionnaires \[demographic, clinical and post-COVID fatigue questionnaire; sleep assessment questionnaires (Epworth sleepiness score \[ESS\], Pittsburg sleep quality index \[PSQI\], Insomnia severity index (ISI)\]) and depression severity questionnaire (the patient health questionnaire-9 \[PHQ-9\]), and conduct cognitive fatigue task. Second assessment meeting: (approximately one hour long) in which the participants will undergo a cardiopulmonary stress test (CPET). Data collection: The main dependent variable will be the presence of continuing fatigue symptoms. The independent variables included demographic and clinical characteristics. The demographic variables will include: age at diagnosis, sex, marital status and number of children, occupational status (employed, unemployed, or retired), education (number of years at school and higher education), and occupation. The clinical variables will include: smoking status, alcohol and cannabis consumption, basic physical function (independent, limited in certain activities, dependent in activities of daily living, or bedridden), background illnesses, and pharmacotherapy. The acute COVID-19 history will be also collected: disease severity according to the WHO criteria, symptoms (sore throat, nasal congestion, headache anosmia/disguesia, cough, shortness of breath, chest pain, gastrointestinal symptoms, and myalgia), need for hospitalization, hospital complications (veno-thromboembolism, super-imposed bacterial infections), for individuals who were not hospitalized - the site of isolation (home, hotel or another isolation facility) will be collected, time from onset to symptoms resolution, pharmacotherapy directed at COVID-19, and information of other household or family members who were also diagnosed. Statistical methods: Demographic and clinical variables of the patients with fatigue symptoms (cases) and control group (free from fatigue symptoms) will be compared using bivariate and multivariable conditional logistic regression models. Independent variables will be selected to be included in the multivariable model based on the bivariate analysis. Odds ratios and 95% confidence intervals will be obtained from the conditional logistic regression models. P\<0.05 will be considered statistically significant. Sample size calculation: Disease severity may serve as a potential risk factor for the development of lasting fatigue symptoms. A preliminary analysis revealed that in our cohort of recovered COVID-19 patients, 20% were hospitalized due to their disease's severity. We will therefore assume that the proportions of individuals required hospitalization during the acute phase were 30% and 10% of the cases and controls, respectively. It is also likely that approximately two thirds of our sample would report on persisting fatigue. Under these assumptions, a sample size of 153 individuals (102 in the cases group and 51 in the control group) will yield a statistical power of 80% at a significance level of 5% for detecting a difference of 0.2 between two proportions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 2, 2021
CompletedFirst Submitted
Initial submission to the registry
April 11, 2021
CompletedFirst Posted
Study publicly available on registry
April 20, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 24, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 24, 2021
CompletedOctober 1, 2021
April 1, 2021
6 months
April 11, 2021
September 30, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Pathological CPET
An abnormal CPET due to either decreased respiratory capacity, muscle weakness or deconditioning
Up to 6 weeks from recruitment and initial testing to CPET testing
Study Arms (2)
Cases
Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), cases will be defined as such if fulfill for the following criteria: individuals who report on lasting fatigue symptoms which appeared following COVID-19, while at least two months have elapsed since COVID-19 diagnosis and the lasting fatigue symptoms are present for at least six weeks.
Controls
Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), did not report fatigue symptoms at any time point following their diagnosis with COVID-19.
Interventions
Cardiopulmonary stress test will be conducted under the guidance of sports and exercise physicians and nursing staff. Electrocardiogram, spirometry, blood pressure and gas exchange measuring will be assessed at rest. The participants will then undergo CPET according to a modified Astrand treadmill test protocol. The test will be terminated at maximal exercise or upon the appearance of limiting symptoms. Continuous electrocardiogram and repeated blood pressure measuring will be conducted at the recovery phase. Post-exercise spirometry will also be assessed.
Eligibility Criteria
Individuals evaluated at Rabin Medical Center's post-COVID-19 clinic for recovered adult individuals.
You may qualify if:
- Adult individuals (age ≥18 years) recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), with or without lasting fatigue symptoms, which appeared following COVID-19, while at least two months have elapsed since COVID-19 diagnosis.
You may not qualify if:
- Individuals hospitalized in intensive care unit and/or required mechanical ventilation during their acute illness.
- Individuals diagnosed with pulmonary veno-thromboembolism/pulmonary infarction, on current oxygen supplementation, with sleep apnea/hypopnea syndrome or with post-COVID-19 chest imaging suggesting pulmonary fibrosis.
- Individuals with heart failure, acute coronary syndrome or percutaneous cardiac intervention during the year prior to the diagnosis.
- Individuals who underwent surgical procedure under general anesthesia during the year prior to the diagnosis.
- Individuals with cerebrovascular disease and a history of cerebrovascular accident or transient ischemic attack.
- Individuals with paralysis of the lower limbs, amputees, bedridden, those assisted with walking aids or wheelchair.
- Individuals with myopathies or myositis, degenerative neurological or muscular diseases, and myasthenia gravis.
- Individuals with pre-COVID-19 diagnosis of chronic fatigue syndrome, fibromyalgia, major depressive disorder, obstructive sleep hypopnea/apnea syndrome, or sleep disturbance necessitating pharmacotherapy.
- Individuals with chronic illnesses (autoimmune diseases and malignancies) necessitating immunosuppression (including corticosteroid therapy) or immunomodulation (including anti-cancer agents).
- Individuals with thyroid dysfunction prior to their diagnosis with COVID-19: uncontrolled hypothyroidism or hyperthyroidism and those with imbalanced thyroid stimulating hormone (TSH) level.
- Pregnant women.
- Individuals with chronic use of opioids.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rabin Medical Center - Beilinson Hospital
Petah Tikva, 49100, Israel
Related Publications (1)
Margalit I, Yelin D, Sagi M, Rahat MM, Sheena L, Mizrahi N, Gordin Y, Agmon H, Epstein NK, Atamna A, Tishler O, Daitch V, Babich T, Abecasis D, Yarom Y, Kazum S, Shitenberg D, Baltaxe E, Elkana O, Shapira-Lichter I, Leibovici L, Yahav D. Risk Factors and Multidimensional Assessment of Long Coronavirus Disease Fatigue: A Nested Case-Control Study. Clin Infect Dis. 2022 Nov 14;75(10):1688-1697. doi: 10.1093/cid/ciac283.
PMID: 35403679DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 11, 2021
First Posted
April 20, 2021
Study Start
March 2, 2021
Primary Completion
August 24, 2021
Study Completion
August 24, 2021
Last Updated
October 1, 2021
Record last verified: 2021-04